TG Therapeutics ($TGTX) Stock Hub: BRIUMVI Growth and the Next Subcutaneous Test

01 TG Therapeutics in September 2026

Revenue rose 70.3% in Q2 while net income fell 72.4% to $7.8 million. Investment explains part of the pressure: the company reports $54.6 million of quarterly subcutaneous manufacturing and second-manufacturer expenses within R&D. This is an expense amount, not the entire year-over-year R&D increase. Higher cost of revenue and interest also reduced profitability.

The company describes itself as a fully integrated commercial-stage biotechnology company focused on B-cell diseases. The practical translation, as of August 2026, is one approved product carrying the whole income statement, three separate attempts to widen it, and a $750 million term loan sitting behind all of it.

What Would Falsify This Reading

The assessment depends on continued product demand, effective development investment and manageable financing costs. The following observations would test it; none is a prediction.

• The BRIUMVI ramp slows. Net product revenue was $235.8 million in Q2 2026 versus $138.8 million a year earlier. Flat or falling quarterly sales would warrant investigation into underlying demand, timing, channel inventory and net pricing. A sustained slowdown without corresponding cost adjustment would weaken the spending case; one quarter alone would not establish that outcome.
• The subcutaneous program fails to deliver. R&D spending includes work across several programs and manufacturing activities. An unsuccessful SC study would weaken a major part of the development case and could leave manufacturing investment underutilized. It would not by itself prove that all research spending was wasted or that the approved IV franchise has failed.
• The debt becomes the constraint. Interest expense rose to $16.6 million in the quarter from $6.7 million, with a $9.2 million loss on extinguishment of debt booked over the half. The company holds $612.3 million of cash and investments and generated $21.4 million of operating cash in the half. A refinancing on worse terms, or a covenant issue, would turn a financing cost into a strategic limit.
• Operating cash flow deteriorates. First-half operating cash flow improved from $21.3 million used to $21.4 million generated. A reversal would require a bridge separating working-capital timing from recurring cash earnings and investment. Persistent consumption would weaken the self-funding case; a single negative quarter would not settle it.

These are observations to evaluate alongside their causes and duration, not automatic invalidation rules or predictions.

02 BRIUMVI: The Label, The Dosing And The Safety Section

BRIUMVI is a glycoengineered monoclonal antibody directed at a specific epitope on CD20-expressing B cells. The removal of certain sugar molecules from the antibody, which the company calls glycoengineering, is intended to allow efficient B-cell depletion at lower doses. That is the mechanistic claim; what matters commercially is the label.

The United States indication, in the exact words of the prescribing information in force, reads: “BRIUMVI is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.” The application is BLA 761238, approved on December 28, 2022 under standard review, with the United States launch in January 2023.

The EU authorisation was granted on May 31, 2023 after the CHMP positive opinion of March 30, 2023. The indication covers adults with active relapsing MS defined by clinical or imaging features. The authorisation holder is Neuraxpharm Pharmaceuticals S.L. The original CHMP opinion document establishes the March date.

Dosing, from Table 1 of the label, is the operational fact that shapes the whole pipeline strategy: a first infusion of 150 mg over four hours, a second infusion of 450 mg two weeks later over one hour, then 450 mg at week 24 after the first infusion and every 24 weeks thereafter, over one hour. Two visits initiate treatment; maintenance follows the label’s 24-week schedule. The three programmes described further down this page — the consolidated single infusion, the subcutaneous formulation and the autoinjector — all exist to shorten that.

The safety section is not decorative and belongs in any honest description of the asset. In the multiple sclerosis trials, infusion reactions occurred in 48 per cent of premedicated patients, with 0.6 per cent serious. The overall infection rate was 56 per cent against 54 per cent on teriflunomide, serious infections 5 per cent against 3 per cent, and there were three infection-related deaths among BRIUMVI-treated patients. The label carries contraindications in active hepatitis B and in patients with a history of life-threatening infusion reaction, and warnings covering hepatitis B reactivation, progressive multifocal leukoencephalopathy, reduction in immunoglobulins and, added in the most recent revisions, clinically significant liver injury reported in the post-marketing setting for anti-CD20 therapies approved in multiple sclerosis, BRIUMVI included.

Recent label supplements include two approvals on August 18, 2025 and one on January 16, 2026; these are not an exhaustive count since launch. Changes include dosing, administration and warnings. The current U.S. label should be consulted for the applicable wording. The company reports biological exclusivity through December 2034 and patent protection extending to 2042. FDA approval and supplement history.

03 ULTIMATE I And II: What The Registrational Data Established, And What It Did Not

Approval rests on two trials, ULTIMATE I and ULTIMATE II, of identical design: randomised, double-blind, double-dummy, parallel-group, active-comparator studies running 96 weeks in patients with relapsing multiple sclerosis. Patients received either BRIUMVI intravenously with an oral placebo, or teriflunomide 14 mg orally once a day with an intravenous placebo. Entry required at least one relapse in the prior year, or two in the prior two years, or a gadolinium-enhancing lesion in the prior year, with a baseline EDSS between 0 and 5.5.

ULTIMATE I randomised 549 patients, ULTIMATE II randomised 545. The primary endpoint in both was the annualised relapse rate.

In ULTIMATE I, the annualised relapse rate was 0.076 on BRIUMVI against 0.188 on teriflunomide, a 59 per cent relative reduction, p<0.001. In ULTIMATE II it was 0.091 against 0.178, a 49 per cent relative reduction, p=0.002. The imaging endpoints were more emphatic still: gadolinium-enhancing T1 lesions per scan at week 96 fell by 97 per cent in both trials, and new or enlarging T2 lesions by 92 and 90 per cent respectively, all at p<0.001.

The disability endpoint did not read out positive, and that matters. In the pooled analysis of both trials, confirmed disability progression at 12 weeks was 5.2 per cent on BRIUMVI against 5.9 per cent on teriflunomide, a 16 per cent risk reduction with p=0.510. The prescribing information states it plainly: there was no statistically significant difference in disability progression between the two arms. The published New England Journal of Medicine analysis gives the same result as a hazard ratio of 0.84 with a 95 per cent confidence interval from 0.50 to 1.41.

These studies establish relapse and lesion effects versus teriflunomide, but did not show a statistically significant pooled disability-progression difference. This result does not establish the performance of every anti-CD20 drug or answer whether a different molecule works in progressive disease.

FDA-label per-trial relapse rates and the EMA public-summary figures use different presentations of the evidence. They should not be interchanged or reconciled by an unverified aggregation assumption. The trial-specific values above follow the current U.S. prescribing information.

04 The Commercial Ramp And What It Is Doing To The Balance Sheet

U.S. BRIUMVI revenue reached $227.7 million in Q2 2026, approximately 64% above the prior-year period according to the company. The $138.843 million comparative in the income statement is total product revenue, including partner sales, and must not be labelled U.S.-only revenue. Approximate U.S. revenue for Q4 2025 was $182 million and full-year 2025 was $594 million.

Two of the intermediate points on that path deserve a caveat, and the chart in this section carries it: the 2025 quarterly figures are company-stated approximations given at an investor presentation, and the first quarter of 2026 is derived by subtracting the reported second quarter from the reported half year. Quarterly approximations remain distinct from reported annual results.

Receivables were $401.6 million at June 30, up $95.9 million in six months, while current and non-current inventory totalled $223.5 million, up $82.184 million on the balance-sheet comparison. Closing receivables divided by quarterly revenue and multiplied by 90 gives roughly 150 days: a simple balance-to-sales proxy, not a reported collection period or DSO based on average balances. Extended customer terms explain part of the working-capital build; no credit-loss allowance was recorded.

Gross margin calculated on total revenue was 82.9%, down from 86.6% a year earlier: margin compression is real. LFB royalty expense was $24.4 million in Q2 and $45.0 million in H1, with $24.3 million payable. The agreement describes tiered mid- to high-single-digit rates on worldwide net sales. The expense must not be divided by TG’s U.S. revenue to infer a contractual royalty rate: the disclosed bases differ.

Outside the United States, the model is different and much smaller. TG sells product to Neuraxpharm, which holds the European marketing authorisation and commercialises there, and receives a royalty in return. In the quarter that was $8.1 million of product sales and $3.6 million of royalty. No sell-through figure for the European market is published by TG, so the size of BRIUMVI’s actual European business is not verifiable from the company’s own disclosures.

05 Guidance Raised Twice, And The Run-Rate Claim

Guidance has been raised twice this year, and the sequence is worth setting out because it is the cleanest available evidence on how the launch is tracking against the company’s own expectations.

On February 26, 2026, with the full-year 2025 results, TG guided to total global revenue of approximately $875 to $900 million for 2026 and BRIUMVI United States net product revenue of approximately $825 to $850 million. On May 6, 2026 those became approximately $925 million and $885 to $900 million. On August 3, 2026 they became approximately $950 million and $890 to $905 million.

The quarterly targets were beaten in both quarters for which one was given. The first-quarter target of about $185 to $190 million of BRIUMVI United States revenue came in at about $194.8 million; the second-quarter target of about $220 million came in at $227.7 million. The August release provides annual guidance rather than a Q3 revenue target.

The cost side of the same guidance moved in the same direction, which is the part that gets less attention. Full-year operating expense, defined by the company as research and development plus selling, general and administrative and excluding non-cash compensation, went from “approximately $350 million” in February and May to “approximately $350 – $400 million” in August, on top of approximately $100 million of subcutaneous manufacturing and second-manufacturer start-up costs. Revenue guidance rose by $25 million; the upper end of the expense guidance rose by up to $50 million.

Beyond 2026 there is no numerical guidance at all. What exists is a statement by the chairman and chief executive, Michael S. Weiss, in the August 3 release: the second quarter puts the company “on track to exit 2026 at an approximately $1 billion annualized U.S. BRIUMVI revenue run rate”. That is an exit run rate, not a 2027 revenue target, and it is a forward-looking statement by management rather than a reported figure. It is quoted here as such.

06 ENHANCE, The Consolidated Infusion, And Why There Is No PDUFA Date

Three separate programmes exist to make BRIUMVI easier to give. The first has already read out.

ENHANCE is a Phase 3, randomised, double-blind, placebo-controlled trial testing whether the two-visit start can be collapsed into one. The primary endpoint was bioequivalence of total drug exposure between the approved regimen — 150 mg on day 1 followed by 450 mg on day 15 — and a single consolidated 600 mg infusion on day 1, measured as area under the curve to week 16 and compared as a geometric mean ratio.

On May 27, 2026 the company announced that ENHANCE met its primary endpoint, with a geometric mean ratio of approximately 1.0 and a 90 per cent confidence interval inside the predefined bioequivalence bounds of 0.80 to 1.25. Secondary endpoints on safety, B-cell depletion and imaging were consistent with prior studies. No infusion reactions of grade 3 or higher occurred in either arm, and infusion reactions were lower than those reported in ULTIMATE I and II, with fewer in the single-infusion arm although the difference between arms was not statistically distinguishable.

The May 27 announcement explicitly targeted an ENHANCE supplemental BLA filing in H2 2026. A submission target is not proof of filing, acceptance or a PDUFA date. The reviewed primary disclosures do not establish an accepted new ENHANCE or SC application with an announced FDA decision date. Previously approved label supplements are separate. Primary source

A related set of data sits in the same category. In November 2024 the company reported that rapid 30-minute infusions were well tolerated, with all infusion-related reactions mild and resolving, and that patients already B-cell depleted on a prior anti-CD20 therapy could switch directly to 450 mg given over one hour without the 150 mg starting dose, with 97 per cent of infusions completed without interruption. Neither schedule is in the label. Table 1 still specifies four hours for the first infusion. No regulatory filing has been announced for the 30-minute infusion.

07 Subcutaneous BRIUMVI: The Largest Call Option The Company Owns

The subcutaneous programme is the largest single call option TG Therapeutics owns, and it is also where the money is currently going.

On June 3, 2026 TG reported Phase 1 results for a high-concentration 400 mg in 2 mL subcutaneous formulation of ublituximab. More than 100 patients were treated in the study, of whom more than 80 received the subcutaneous route across doses from 50 mg to 400 mg, with over 225 subcutaneous injections given and more than three quarters of them at the full 400 mg. Mean bioavailability was greater than 60 per cent relative to intravenous administration, with the lower bound of the 95 per cent confidence interval above 55 per cent. Kinetics were linear across the dose range.

Local injection-site reactions occurred in fewer than 5 per cent of patients and systemic injection-related reactions in about 21 per cent, not dose-dependent, mostly at the first injection, and resolving in all patients. No serious injection-site reactions and no new safety signals were reported.

The Phase 3 is NCT07211633, a randomised, open-label, parallel-group non-inferiority study with three arms: intravenous BRIUMVI on the approved schedule, subcutaneous 400 mg every eight weeks, and subcutaneous 400 mg every twelve weeks. The primary endpoint is exposure to week 24, with non-inferiority declared if the lower bound of the 90 per cent confidence interval of the geometric mean ratio exceeds 0.80. Enrolment is complete. Modelling from the Phase 1 data projects a geometric mean ratio of about 1.21 for the quarterly regimen with a lower bound of 1.15, and about 1.58 for the every-eight-weeks regimen with a lower bound of 1.50.

Topline is guided for year-end 2026 or the first quarter of 2027. Weiss has spoken of advancing toward a potential approval in 2028. A device bridging study for an autoinjector, NCT07503873, has been recruiting since April 2026 with primary completion estimated for July 2027.

The strategic claim attached to this programme — that a subcutaneous option “could nearly double the addressable market opportunity for the BRIUMVI franchise” — is a company statement about an unapproved product and is reported here as that, not as an estimate anyone has verified. What can be said without stretching is that the competitive target is specific: Kesimpta, ofatumumab, Novartis, which is the anti-CD20 that patients administer themselves at home. Ocrevus Zunovo, the subcutaneous ocrelizumab from Genentech, is given by a healthcare professional and sits in a different position.

08 Myasthenia Gravis, Schizophrenia And What Is No Longer In The Pipeline

Two new indications entered the clinic in the space of two months, both using the approved molecule in diseases where B-cell depletion has a mechanistic rationale.

Myasthenia gravis. The company reports a randomized Phase 2 evaluating IV BRIUMVI maintenance after efgartigimod induction. NCT07673744 lists recruiting status and 120 planned participants. Its September 22, 2026 update moved the estimated start to October 1, 2026; estimated primary completion remains July 1, 2028. Recruiting status and an estimated start are not confirmation that the first patient has been dosed. The August results release also characterizes earlier SC Phase 1 MG data as positive; that headline does not establish successful Phase 2 efficacy or a new approved indication.

Schizophrenia. NCT07680946 is a Phase 2 in treatment-resistant schizophrenia, with 60 participants planned. The September 23 registry update gives an actual start of July 27, 2026 and estimated primary completion December 12, 2028. This remains an early immunological hypothesis; no efficacy results were verified.

The pediatric relapsing-MS programme NCT07220252 is recruiting, with 240 participants planned and estimated primary completion January 2030. Planned enrolment is not a count of patients already treated.

These expansion programmes have longer development horizons than the upcoming subcutaneous readout. Estimated primary-completion dates do not establish when interim data or a final publication will appear; no precise readout commitment for these indications was verified.

09 Azer-cel: The Only Asset That Is Not Ublituximab

Azer-cel, azercabtagene zapreleucel, is the one asset in the pipeline that is not ublituximab. It is an allogeneic, off-the-shelf CAR-T directed at CD19, built from donor T cells using the ARCUS genome-editing technology and designed to avoid graft-versus-host disease.

The Precision licence covers autoimmune disease and other non-oncology indications. The initial $7.5 million comprised $5.25 million cash and a $2.25 million equity investment in Precision; a further $2.5 million equity investment followed in January 2025. Milestone 1 was achieved and paid on February 23, 2026: another $7.5 million, split $5.25 million cash and $2.25 million equity investment. That completed payment is not an additional future obligation. Further contingent development and commercial payments and royalties remain under the licence.

The FDA cleared the autoimmune azer-cel IND in 2024. The live NCT06680037 record, updated September 9, 2026, lists an actual study start of May 6, 2025, recruiting status, 100 planned participants and estimated primary completion December 1, 2026. A registry start is not necessarily the date of first dosing. The long-term follow-up record NCT07577583 remains not yet recruiting, with an estimated May 2027 start. None of these registry dates is a company-announced readout date.

The near-term item is presentational: TG has committed to present preliminary Phase 1 azer-cel data in progressive multiple sclerosis in the second half of 2026. That commitment was made in January and repeated on August 3. It is one of only three remaining 2026 pipeline milestones the company lists, the others being the full ENHANCE results and the subcutaneous Phase 3 topline.

Progressive MS is a distinct clinical challenge. The pooled disability endpoint in ULTIMATE did not show statistical significance, but those relapsing-MS trials do not establish whether azer-cel works in progressive disease. Small, early Phase 1 observations will require cautious interpretation and longer follow-up.

10 The Second Quarter Of 2026, Line By Line

The second quarter of 2026, reported on August 3 and filed in full on August 5, reads as follows.

Revenue. Product revenue net was $235.794 million against $138.843 million a year earlier. Licence, milestone, royalty and other revenue was $4.541 million against $2.305 million. Total revenue $240.335 million against $141.148 million, up 70.3 per cent.

Costs. Cost of revenue $41.194 million. Research and development $95.337 million, of which $8.070 million is stock-based compensation. Selling, general and administrative $82.130 million, of which $19.805 million is stock-based compensation. Total costs and expenses $218.661 million against $106.305 million.

Below the operating line. Operating income $21.674 million against $34.843 million. Interest expense $16.572 million against $6.716 million, the consequence of replacing a $250 million loan with a $750 million one. Other income $5.132 million. Net income before taxes $10.234 million, income tax expense $2.453 million, net income $7.781 million. Earnings per share $0.05 both basic and diluted, on 141.8 million basic and 157.3 million diluted weighted-average shares.

The cascade has been recomputed line by line and reconciles: 235.794 plus 4.541 gives 240.335; 41.194 plus 95.337 plus 82.130 gives 218.661; 240.335 less 218.661 gives 21.674; 21.674 less 11.440 of net other expense gives 10.234; less 2.453 of tax gives 7.781.

Stock-based compensation across both operating lines totalled $27.875 million in the quarter, equal to 11.6 per cent of revenue, and $47.825 million in the half. It is a real cost of running this company even though it does not consume cash, and the company’s own operating expense guidance is stated before it.

Cash generation. For the first half, net cash provided by operating activities was positive $21.369 million, against negative $21.279 million in the first half of 2025 — a swing of $42.6 million. Capital expenditure was $0.344 million, so free cash flow for the half was about $21.0 million. Deriving the second quarter alone by subtracting the first quarter’s disclosed $17.9 million of cash use gives roughly $39.3 million generated in the second quarter, a calculation rather than a published figure.

The gap between $27.6 million of half-year net income and $21.4 million of operating cash is working capital: receivables absorbed $95.9 million and inventory $80.1 million, offset by $99.4 million of growth in payables and accruals and $47.8 million of non-cash compensation added back.

11 The Blue Owl Loan And A Balance Sheet That Changed Shape

The balance sheet changed shape completely in March 2026, and the change is the most consequential financial event of the year for this company.

On March 18, 2026 TG drew a $750 million term loan under a First Amendment to its financing agreement with Blue Owl, using part of the proceeds to repay in full the $250 million initial term loan taken in August 2024. The new facility matures March 18, 2031. Quarterly amortisation of $37.5 million begins with the quarter ending March 31, 2030, with a balloon at maturity, and those instalments can be deferred if a total net leverage ratio falls below an agreed threshold. Pricing starts at 4.75 per cent over the SOFR-linked option, with a 25 basis point step-down on reaching a leverage threshold, reset quarterly. The loan is secured on substantially all assets of the company and certain guarantor subsidiaries. An additional uncommitted facility of up to $250 million sits alongside it. At June 30 the company states it was in compliance with all financial covenants.

The refinancing generated a $9.153 million accounting loss on extinguishment in Q1, which should not be described as a cash repayment fee of the same amount. New financing costs were approximately $4.9 million. The term loan carrying value was $745.387 million after unamortized discounts and issuance costs.

The $750 million term-loan principal less $612.3 million cash, equivalents and investment securities gives approximately $137.7 million net term debt. This definition excludes the legacy convertible notes described below, which carry no cash repayment obligation. Equity was $604.083 million versus $648.020 million at December 31, despite positive H1 income, with repurchases affecting equity.

Legacy 5% convertible notes have $15.5 million principal and a $1,125 conversion price, approximately 13,800 underlying shares. The filing explicitly states no cash repayment obligation; their fair-value liability was $1.301 million. They should not be combined mechanically with the cash-pay term loan. Hercules warrants cover 115,042 shares at $17.95 and 50,172 at $14.70.

The automatic Form S-3ASR shelf filed August 8, 2025 was effective on filing and registered an unspecified amount of debt, equity and other securities. The filing reports no issuance under it through June 30, 2026 and says the prior ATM programme expired. Shelf registration permits potential offerings; it does not supply cash, assure investor demand or override offering terms, applicable restrictions or market conditions. Future equity issuance could dilute holders, while debt issuance would add obligations.

12 A Share Count That Is Shrinking, And Q2 Buyback Activity

Shares outstanding fell from 155,305,953 at December 31, 2025 to 153,077,784 at June 30, 2026 and 153,069,053 at August 3, 2026. On the comparable balance-sheet dates, issued shares rose from 158,849,596 to 159,949,330 while treasury shares increased. Repurchases more than offset issuance over that period; the June issued-share count should not be relabeled as an August observation. Weighted-average diluted shares fell from approximately 162.5 million in H1 2025 to 158.7 million in H1 2026.

The first $100 million repurchase programme was completed in September 2025, purchasing 3,502,334 shares at an average $28.55. Repurchased shares should not automatically be called retired: treasury shares remained on the June balance sheet. The second programme was increased to $300 million in March 2026; roughly $100 million was spent, with treasury stock totalling 6,871,546 shares at $200.2 million cost.

No shares were repurchased in April, May or June, and $200,008,004 remained authorised at June 30. This establishes zero Q2 activity, not a formal suspension or management’s valuation judgment. Future repurchases remain discretionary and compete with development and other cash needs.

At June 30 there were 11,220,924 restricted shares, 4,060,156 options and 1,949,005 stock tracking units. These counts are not additive incremental dilution: restricted shares can already be included in issued shares, while options require exercise and tracking units may settle in cash or shares. Tracking-unit expense was $15.3 million in Q2, including $8.6 million remeasurement; unrecognised cost was $84.8 million over an average 3.6 years.

Reported insider activity needs the transaction code and footnote. The September 14 Form 4 reports Laurence Charney sold 5,000 shares on September 10 at a weighted-average $54.96. Its footnote says the restricted-stock administrator sold them to satisfy his income-tax obligations. This is a reported sale, not evidence of a discretionary bearish view. The previously disclosed August gifts are a different transaction type. September Form 4

13 Market Data, Ownership And Retail Sentiment

Finviz read October 2, 2026: market capitalization 8.24B USD; provider shares 153.08M, float 141.64M, short float 21.29% (30.15M shares short), short ratio 14.70; institutional ownership 72.96%, insider ownership 7.47%. The previous regular-session close was $53.62 on October 1. Provider fields can lag underlying filings; the reading date is not the short settlement date. Provider shares remain distinct from dated SEC shares. Ownership reports may overlap and do not form an exclusive allocation of the capital. Finviz.

The April proxy reports BlackRock 20,134,882, Vanguard 15,596,480 and State Street 8,100,619 shares. Michael Weiss’s 11,544,752 beneficial shares include 5,995,707 unvested restricted shares and 1,766,666 option shares: this is not the same as freely tradable stock.

Vanguard’s March zero-share amendment reflected an internal reporting reorganisation. Vanguard Portfolio Management’s April filing for 8,400,210 shares has a different reporting scope; it does not by itself prove a sale from 15.6 million to 8.4 million.

Retail discussion reflects opinion and attention; it does not establish a clinical result, regulatory approval or commercial demand.

StockTwits live stream · Finviz reference (affiliate)

14 The Anti-CD20 Field And Where BRIUMVI Sits In It

The principal approved anti-CD20 competitors listed by TG comprise three products based on two other antibodies: ocrelizumab in intravenous and subcutaneous presentations, and ofatumumab.

OCREVUS, ocrelizumab, Genentech, BLA 761053, approved March 28, 2017, intravenous. OCREVUS ZUNOVO, ocrelizumab with hyaluronidase, Genentech, BLA 761371, approved September 13, 2024, subcutaneous and administered by a healthcare professional. KESIMPTA, ofatumumab, Novartis, approved for multiple sclerosis on August 20, 2020 as supplement 70 to BLA 125326, subcutaneous and self-administered by the patient.

The 2025 Form 10-K states the position in the company’s own words: BRIUMVI directly competes with ocrelizumab, the only other approved intravenously administered anti-CD20 antibody, and with the subcutaneous version of ocrelizumab given by healthcare providers; it also competes with ofatumumab, and ofatumumab “would represent direct competition for any future self-administered subcutaneous formulation of ublituximab currently under development”.

A potential home-administered ublituximab presentation would compete particularly with self-administered ofatumumab, while remaining part of the broader anti-CD20 market. Every-eight- or every-twelve-week dosing is investigational; commercial differentiation depends on successful trials, approval, access and adoption.

The 2025 annual report also identifies BTK inhibitors and CD40-ligand approaches as emerging competitive risks. This is the company’s dated competitive assessment, not a real-time regulatory-status statement for every asset in those classes.

Two clarifications for accuracy. Rituximab is not FDA-approved for multiple sclerosis; it is used off-label in some settings and the company does not list it among approved competitors. And no market share figure for the anti-CD20 class appears in any primary source examined for this page — the only related statement on record is a management objective, not a measurement.

15 The Catalyst Map To 2028

The September investor appearances are historical. The forward calendar below separates company guidance from estimated registry completion dates. Neither type is an FDA decision date.

The September 21 updates list ENHANCE as recruiting with estimated primary completion January 21, 2027, and SC Phase 3 as active, not recruiting, with estimated primary completion October 31, 2026. The broader ENHANCE record and its randomized cohort reported in May have different scopes. These completion estimates are not announced result-release dates.

16 Risks And Red Flags

Concentration. One product, one country, 95 per cent of revenue. Every operational risk that attaches to BRIUMVI attaches to the whole income statement at once.

Leverage. $750 million of secured debt against $612.3 million of cash. Interest expense more than doubled year on year to $16.6 million in the quarter and is now large enough to consume most of operating income: $21.7 million of operating income against $11.4 million of net other expense. Amortisation of $37.5 million a quarter begins in 2030. The loan is secured on substantially all assets.

Working capital. Receivables and inventory grew substantially in H1. The approximately 150-day closing-balance-to-quarterly-sales proxy is not a reported collection period. Cash conversion requires monitoring even while accounting revenue grows.

Royalty and margin. LFB royalty expense was $24.4 million, approximately 59% of Q2 cost of revenue. The tiered worldwide royalty affects economics, but margin also depends on product and geographic mix and other manufacturing costs.

Spending ahead of evidence. The company expects approximately $100 million of manufacturing expense in 2026 for the SC programme and work with a secondary manufacturer. An unsuccessful pivotal study could reduce the value of part of this investment; the amount is a 2026 forecast, not a perpetual annual commitment or proof that every dollar depends on one trial.

Shelf capacity. The automatic S-3ASR provides financing flexibility but does not establish an imminent issuance. Any issue remains subject to applicable law, contractual terms and company decisions.

Label and safety. The current U.S. label is revised January 2026 and includes infection, hepatitis B, immunoglobulin and liver-injury precautions. The registrational programme recorded three infection-related deaths. Clinical and regulatory success does not remove these treatment risks.

Governance signal. At the June 11, 2026 annual meeting all directors were re-elected, but two drew unusually high withheld votes: Sagar Lonial at 54.85 per cent for and 45.15 per cent withheld, and Kenneth Hoberman at 65.52 per cent for. The advisory executive-compensation proposal was not approved. The company has only two executive officers, and the chairman is also chief executive and president.

Rumour risk. Takeover speculation appears in the retail stream reviewed, but no primary announcement confirming a transaction was found. Posts do not establish a deal or explain how much of the share-price movement it caused.